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Abstract: 
 
Major Depressive Disorder (MDD) involves changes in appetite and weight, with a subset of 
individuals at an increased risk of weight gain. Pathways to weight gain may include appetite 
disturbances, excess eating, and dysregulation of appetite hormones. However, little research 
has simultaneously examined relationships between hormones, eating behaviours and MDD 
symptoms. Plasma ghrelin and leptin, biometrics, eating behaviours and psychopathology 
were compared between depressed (n = 60) and control (n = 60) participants. Depressed 
participants were subcategorised into those with increased or decreased appetite/weight for 
comparison by subtype. The Dutch Eating Behaviours Questionnaire and Yale Food 
Addiction Scale measured eating behaviours. Disordered eating was higher in MDD than 
controls, in females than males, and in depressed individuals with increased, compared to 
decreased, appetite/weight. Leptin levels were higher in females only. Leptin levels 
correlated positively, and ghrelin negatively, with disordered eating. The results provide 
further evidence for high levels of disordered eating in MDD, particularly in females. The 
correlations suggest that excessive eating in MDD is significantly linked to appetite 
hormones, indicating that it involves physiological, rather than purely psychological, factors. 
Further, longitudinal, research is needed to better understand whether hormonal factors play a 
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1. Introduction: 
 
Research indicates that obesity increases the risk of Major Depressive Disorder 
(MDD) by approximately 18-55%, and in turn, MDD increases the risk of obesity by 
approximately 37-58% (Luppino et al., 2010; Heiskanen et al., 2013; Mannan, Mamum, Doi 
& Clavarino, 2015). The prevalence rates of both MDD and obesity are increasing annually, 
with these rises attributed to physiological and psychological stress, obesogenic environments 
and changes in modern lifestyles (Hidaka, 2012). Consequently, individuals with MDD are at 
increased risk of developing additional health complications, including cardiovascular 
disease and metabolic syndrome (Cassano & Fava, 2002; Penninx et al., 2013). Identifying 
potential mechanisms for weight gain in MDD may help improve interventions aimed at 
reducing the likelihood of chronic disease in these at-risk individuals. 
Changes in appetite and weight are diagnostic criteria for MDD (American 
Psychiatric Association, 2013), with the direction of appetite/weight changes differing by 
MDD subtype. Melancholic MDD is characterised by decreased appetite and weight loss. In 
contrast, atypical MDD features hyperphagia, weight gain (American Psychiatric 
Association, 2013), higher BMI values, increased endocrine dysregulation and more frequent 
instances of cardiovascular disease and metabolic syndrome (e.g. Gecici et al., 2005; Lamers 
et al., 2016; Milaneschi et al., 2017). Epidemiological studies have indicated that atypical 
MDD is now 40% more prevalent than melancholic MDD; indicating that ‘atypical’ 
symptoms, including weight gain, are increasingly becoming more ‘typical’ (Blanco et al., 
2012; Privitera et al., 2013). Despite clearly established risks for chronic disease (Cassano & 
Fava, 2002; Penninx et al., 2013), there is a lack of both specific treatment guidelines for the 
treatment or prevention of depressogenic weight gain, and integrated approaches that address 
both biological and physiological factors. The long-term success of weight loss programs in 
general is also limited (MacLean et al., 2015). Understanding the mechanisms underlying the 
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pathways to weight gain in MDD may allow for better preventative strategies in individuals 
at risk due to MDD. 
Pathways to weight gain in MDD may include appetite disturbances linked to 
neuroendocrine changes and associated disordered eating. Disordered eating may act as a 
coping mechanism for psychological distress, as foods, particularly those high in 
carbohydrates, can dampen physiological stress responses produced by the hypothalamic-
pituitary-adrenal (HPA) axis (e.g. Dallman et al., 2003). Disordered eating includes 
emotional eating, increasing food intake in response to emotional distress; restrained eating, 
deliberately restricting food intake to prevent weight gain or encourage weight loss; and 
external eating, increasing food intake in response to sensory food cues (van Strien et al., 
2016). Depressed mood and MDD symptom severity are associated with emotional eating 
(e.g. van Strien et al., 2016; Paans et al., 2018), increased consumption of food in response to 
external cues, and with restricting food intake (e.g. Sevincer et al., 2017).  
Food addiction characterises a subset of disordered eating behaviours, defined by a 
preference for highly palatable foods and addiction-like behaviours such as a loss of control 
and withdrawal (Piccini et al., 2015). Dopaminergic reward pathways can be activated by 
highly palatable foods, particularly those high in carbohydrates or fat, which can result in 
addiction-like behaviours similar to substance use disorders (e.g. Gearhardt, Corbin & 
Brownell, 2009; Piccini et al., 2015). Food addiction can be measured using the Yale Food 
Addiction Scale (YFAS; Gearhardt et al., 2009), with a prevalence of 5-10% in the general 
population, and 15-25% in obese individuals (Meule & Gearhardt, 2014; Hauck et al., 2017). 
In a recent pilot, we found that 25% of a sample with MDD met Yale criteria for food 
addiction, considerably higher than general community samples (Mills et al., 2018).  
The concept of food addiction is still controversial, since food is necessary for 
survival whereas psychoactive substances that form the basis of other addictions are not (e.g. 
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Ziauddeen & Fletcher, 2013: Onaolapo & Onaolapo, 2018). The composition of modern 
foods has been altered to increase their palatability and hedonistic qualities compared to 
naturally occurring foods (Leigh & Morris, 2018), to the extent that they could be argued to 
act similarly to addictive substances. There is increasing evidence of an overlap between 
activation of neural reward circuitry in response to food and drugs of addiction (e.g. 
Gearhardt et al., 2011; Volkow et al., 2012). Several studies have linked the concept of food 
addiction to MDD (e.g. Gearhardt et al., 2012; Eichen et al., 2013; Mills et al., 2018). As 
such, it is possible that obesogenic environments promoting the availability of highly 
palatable foods may be related to the increased prevalence of atypical MDD characterised by 
weight gain, however further research is needed. 
While previous studies indicate that MDD is associated with disordered eating (e.g. 
Bailly et al., 2012; van Strien et al., 2016), food addiction (e.g. Eichen et al., 2013; Mills et 
al., 2018) and weight gain (e.g. Blanco et al., 2012), the mechanisms underlying the 
relationships between these factors are unclear. The hunger and satiety hormones ghrelin and 
leptin are related to HPA axis activity and suppression of stress responses, and therefore may 
be associated with MDD and associated symptomatic appetite/weight changes (Roubos et al., 
2012; Spencer et al., 2014). However, little research has examined direct relationships 
between these hormones, disordered eating behaviours and appetite/weight changes in MDD. 
Leptin is secreted by adipocyte cells in proportion to adipose tissue mass, with critical 
roles in regulating adipose tissue and body weight (Maffei et al., 1995). Leptin has important 
anorexigenic effects, acting as an appetite suppressant during times of energy excess (Elmqist 
et al., 1998; Trayhurn et al.,, 1999; Lu, 2007). Leptin resistance, or having high leptin levels 
but decreased leptin sensitivity (e.g. Pan et al.,, 2014) has been implicated in the pathogenesis 
of obesity (Zigman & Elmquist, 2003; Ozsoy et al., 2014). Since leptin is secreted relative to 
adipose tissue mass, higher levels signal the increased availability of fat and in turn lead to a 
Weight Gain in MDD 7 
reduction in food intake such that stored fat can be utilised for energy. However, in leptin 
resistance individuals become desensitised to endogenous satiety signals, resulting in 
elevated leptin levels without the usual satiety, and subsequently increased food intake and 
weight gain or obesity (e.g. Maffei et al., 1995).  
Human research investigating leptin levels in MDD has identified inconsistent results, 
with either lower (e.g. Kraus et al., 2001; Atmaca et al., 2003; Westling, et al., 2004) or 
elevated (e.g. Antonijevic et al., 1998; Jimenez et al., 2009; Morris et al., 2012) leptin levels 
in MDD versus control populations. In contrast, several studies, including large-scale meta-
analyses, have indicated no difference between diagnostic groups (e.g. Hafner et al., 2012; 
Ozsoy et al., 2014; Carvalho et al., 2014). Individuals with atypical MDD have higher leptin 
levels compared to controls, and individuals with melancholic MDD (e.g. Gecici et al., 2005; 
Lamers et al., 2016a; Milaneschi et al., 2017), suggesting that leptin may be involved in a 
subset of individuals with increased appetite/weight. 
Ghrelin is secreted from the stomach and gastrointestinal tract (Kojima et al., 1999), 
with important orexigenic roles in promoting increased food intake (e.g. Wren et al., 2000) 
and increased adiposity (e.g. Tschop et al.,, 2001; Thompson et al., 2004). Significantly lower 
total ghrelin concentrations have been observed in obese humans, indicating possible 
downregulation of ghrelin levels associated with excessive eating (e.g. Atalayer et al., 2013).  
Studies of ghrelin in MDD are also inconsistent, with elevated (e.g. Kurt et al., 2008; 
Atescelik et al., 2017; Ozsoy et al., 2014) lowered (e.g. Barim et al., 2009) or no difference 
between MDD and control participants observed (e.g. Kluge et al., 2009; Lawson et al., 2011; 
Matsuo et al., 2012). Whether ghrelin levels differ by melancholic/atypical subtype is 
currently unclear, however due to its role in stimulating appetite levels (e.g. Wren et al., 
2000) ghrelin levels may possibly be higher in those experiencing appetite/weight gain, or 
possibly lowered due to the downregulation observed in obesity (Atalayer et al., 2013).  
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The inconsistent results for leptin and ghrelin levels may be accounted for by the 
heterogeneity in appetite/weight change symptom profiles in MDD. Previous studies have 
either combined symptom subtypes (e.g. Antonijevic et al., 1998; Ozsoy et al., 2014) or have 
classified symptoms based on broader atypical MDD criteria, differing also in the 
classification methods used (e.g. Gecici et al., 2005; Lamers et al., 2016; Milaneschi et al., 
2017). These inconsistent classification methods may act as potential confounds in these 
studies. In addition, leptin levels are more strongly correlated with appetite and weight gain 
and not other atypical symptoms (e.g. Milaneschi et al., 2017), suggesting that comparison by 
appetite/weight symptom profile may provide a clearer understanding of relationships 
between appetite hormones and weight gain than atypical criteria more generally. 
Leptin and ghrelin are noted to vary between sexes, with higher leptin and ghrelin 
levels reported in females than males (e.g. Antonijevic et al., 1998; Soriano-Guillen et al., 
2016); which may be explained by females having different body fat compositions than males 
for reproductive purposes (Blaak, 2001). However, sex differences in leptin and ghrelin 
levels are not always observed (e.g. Kluge et al., 2009; Tschop et al., 2001). In humans, 
leptin and ghrelin levels have also previously been correlated with body mass index (BMI) 
and waist circumference (e.g. Mills et al., 2018; Akamizu et al., 2004), suggesting potential 
roles for both hormones as risk factors for chronic diseases. However, no studies have 
simultaneously examined associations between appetite hormones, disordered eating and 
BMI in MDD.  
Our previous pilot study (Mills et al., 2018) found that a high proportion of 
participants with MDD reported disordered eating, including emotional and restrained eating 
as measured by the Dutch Eating Behaviours Questionnaire (van Strien et al., 1986), and food 
addiction behaviours as measured by the Yale Food Addiction Scale (Gearhardt et al., 2009). 
Disordered eating was higher in females with MDD than males with MDD. Further, 
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disordered eating correlated positively with leptin levels, suggesting that leptin resistance 
may be involved in disordered eating in MDD. The current study expands on our previous 
work by investigating eating behaviours in relation to neurobiological measures in a new 
cohort. Leptin and ghrelin levels, biometrics and psychometric indices of mood and 
problematic eating behaviours were compared between individuals with MDD and healthy 
controls. Given the heterogeneous nature of MDD, participants with MDD were further 
subcategorised by appetite/weight symptom presentation to compare subtypes. It was 
predicted that: 
 
1. Participants with MDD would report greater levels of disordered eating compared to 
controls. By symptom profile, MDD participants with increased appetite/weight 
would demonstrate higher instances of these behaviours than MDD participants 
without increased appetite/weight; with effects being greater in females. 
2. Psychometric indices of problematic eating behaviours, food addiction and depression 
severity will correlate with leptin and ghrelin levels.  
3. Leptin and ghrelin levels would not differ significantly between depressed and non-
depressed participants overall. However, at the subgroup level in MDD, these values 
will be higher in those with increased appetite/weight compared to those with reduced 






One hundred and twenty (120) adults aged between 18 and 54 years (M = 25.05, SD = 
6.61 years; 68 female) participated. Participants were recruited by media and university 
advertisements. Depressed participants were pre-screened to confirm that they currently met 
DSM-5 criteria prior to inclusion in the MDD group (N = 60). Control participants (N = 60) 
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were age and gender matched to the MDD group. Depressed participants were not receiving 
any current or recent psychological, pharmacological or somatic treatment for MDD. All 
control participants had no history of diagnosed mental disorders. Use of corticosteroids, 
neurological illness and substance use were general exclusion criteria. Participants were 
asked to provide information about any medical conditions and medications being taken. The 




Depressive symptom severity was assessed using the Beck Depression Inventory 
(BDI-II), a 21 item self-report questionnaire (Beck et al., 1996). Disordered eating, including 
Emotional, Restrained and External eating, were measured using the Dutch Eating 
Behaviours Questionnaire (DEBQ; van Strien et al., 1986). Food addiction and related 
behaviours, including Withdrawal symptoms, Cravings and Tolerance to increased food 




Participants attended one visit at the university clinical trials research unit. All 
participants provided informed written consent. Depressed participants were interviewed to 
confirm that they met criteria for MDD using the Mini Neuropsychiatric Interview, version 
7.0.2 for DSM-5 (MINI; Sheehan, 2015). Depressed participants were asked to indicate 
whether they had experienced any recent changes to their appetite or weight. To meet the 
criteria for increased or decreased/unchanged appetite/weight, MDD participants were 
required to endorse a 5% (or 3 kilogram) increase or decrease to their weight that was not the 
result of deliberate weight changes, such as intentional weight loss, in the previous month 
(Sheehan, 2015).  
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Participants’ height, weight, waist circumference, blood pressure and heart rate were 
measured, then a 10ml blood sample was obtained by a phlebotomist. All blood samples were 
taken between 9:00-11:00am. Participants were not required to fast, however details of food 
consumption in the previous 12h were recorded. Participants then completed the 
psychometric questionnaires. 
 
2.4 Data and Statistical Analysis 
 
Blood samples were centrifuged at 4°C, at 2800rpm for 10 min immediately 
following blood collection. Plasma was stored in a -80°C freezer until analysis. Plasma leptin 
and total ghrelin levels were measured using standard ELISA testing kits (Abcam, 
Cambridge, United Kingdom and Thermofisher Scientific, Carlsbad, United States of 
America respectively). The intra- and inter-assay coefficients of the leptin ELISA were <10% 
and <12% respectively, and <6% and <8.5% for the total ghrelin ELISA. 
Statistical analysis was conducted using ‘Statistical Package for the Social Sciences’ 
(SPSS, Version 23). The dependent variables of interest were the psychometric 
measurements (BDI, DEBQ and YFAS scores), plasma leptin and total ghrelin levels. Due to 
the relationship between leptin and adipogenesis (e.g. Maffei et al., 1995), to control for 
potential confounding effects of visceral fat, plasma leptin was normalised to waist 
circumference (in metres) prior to statistical analysis.  
Two-way factorial analyses of variance (ANOVA) were used to test for differences in 
the dependent variables with the between-subjects factors of Diagnosis (MDD, control) and 
Sex (male, female), with Age and BMI used as covariates. Further two-way factorial 
ANOVAs were used to test for subgroup differences in the variables as a function of appetite 
and weight changes in MDD participants only, with the between-subjects factors of Appetite 
and Weight Categories (increased, decreased/no change) and Sex (male, female), with Age 
and BMI also as covariates. Pearson’s correlation coefficients and Spearman’s rank 
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correlations were used to determine relationships between the variables. For all statistical 





3.1 Analyses of MDD (combined subtypes) compared to controls: 
 
3.1.1 Demographic and Biometric Data 
 
Participant characteristics are shown in Table 1. There were 34 females and 26 males 
in both MDD (N = 60) and control (N = 60) groups. No participants had a diagnosed eating 
disorder, and none were current smokers. Of the 120 participants, 30 (18 MDD) had not 
consumed any food or drink other than water for approximately 12h.  
The groups did not differ significantly in age. Males weighed more than females (F(1, 
116) = 18.159, p < .001). No further differences for Diagnosis, Sex or interaction effects were 
significant for biometric data (Table 1). 
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Table 1:  
Means and standard deviations for biometric data, by Diagnosis and Sex (total N = 120; MDD and control participants).  
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index. * Indicates a significant difference compared to the other diagnostic group 





  Diagnosis Sex 
Variable  Control MDD Effect Effect Size Male Female Effect Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample size (n) 60 60 - - 52 68 - - 
Biometrics Age (years) 25.40 (7.17) 24.70 (6.03) 0.422 0.006 25.31 (5.38) 24.85 (7.44) 0.709 0.001 
 Weight (kg) 73.29 (16.67) 74.65 (16.13) 0.721 0.001 80.79 (13.98)* 68.76 (16.18) < 0.001 0.135 
 BMI (kg/m2) 25.10 (5.35) 25.80 (5.41) 0.580 0.003 25.51 (4.35) 25.40 (6.06) 0.910 0.000 
 Waist Circumference (m) 0.89 (0.14) 0.85 (14.30) 0.150 0.018 0.90 (0.12) 0.82 (0.13) 0.071 0.028 
Weight Gain in MDD 14 
3.1.2 Psychometric Data 
Participants with MDD had significantly higher Total BDI scores compared to 
controls (F(1, 116) = 354.013, p < .001). Females had higher Total BDI scores than males 
(F(1, 116) = 4.860, p = .029). The interaction between Diagnosis and Sex was not significant.  
Depressed participants scored significantly higher on the Emotional (F(1, 116) = 
20.194, p < .001) and Restrained (F (1, 116) = 9.576, p = .002) subscales of the DEBQ 
compared to controls. Females also scored significantly higher on the Emotional (F(1, 116) = 
10.392, p = .002) and Restrained (F (1, 116) = 6.268, p = .014) subscales compared to males. 
External eating did not differ between diagnostic groups or sexes. No interaction effect 
between Diagnosis and Sex was observed for any DEBQ subscales. 
Endorsement rates for each YFAS symptom are presented in Table 3. Seventeen 
(28%; 13 female) MDD participants met the YFAS criteria for food addiction compared to 
two (3%; both female) of controls. Overall, participants with MDD had significantly more 
food addiction symptoms than controls (F(1, 116) = 22.139, p < .001), and scored 
significantly higher than controls on each YFAS subscale, with the exception of Continued 
Use Despite Problems. Withdrawal scores were significantly higher in females compared to 
males (F(1, 116) = 4.208, p = .042), with no further differences by Sex, and no interaction 
effects identified (Table 2).
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Table 2:  





Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale 
Food Addiction Scale. YFAS subscales are scored dichotomously and occur between 0.00 and 1.00. * Indicates a significant difference compared to 
the other diagnostic group or sex being compared. 
  Diagnosis Sex 
Psychometrics  Control MDD Effect Effect Size Male Female Effect Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample size (n) 60 60 - - 52 68 - - 
BDI Total Score 4.80 (4.75) 30.72 (9.59)* < 0.001 0.753 16.06 (13.82) 19.06 (15.88)* 0.029 0.040 
DEBQ Emotional Eating 1.99 (0.72) 2.75 (1.11)* < 0.001 0.148 2.07 (0.95) 2.60 (.99)* 0.002 0.082 
 Restrained Eating 1.94 (0.83) 2.49 (1.07)* 0.002 0.076 1.97 (0.93) 2.40 (1.01)* 0.014 0.051 
 External Eating 2.98 (0.71) 3.20 (0.67) 0.117 0.021 3.08 (0.72) 3.10 (0.69) 0.923 0.000 
YFAS Increased Intake 0.13 (0.34) 0.33 (0.48)* 0.012 0.053 0.27 (0.45) 0.21 (0.41) 0.410 0.006 
 Failure to Quit 0.10 (0.30) 0.37 (0.49)* 0.001 0.093 0.15 (0.36) 0.29 (0.46) 0.059 0.030 
 Time Taken to Obtain 0.10 (0.30) 0.37 (0.49)* 0.001 0.096 0.27 (0.45) 0.21 (0.41) 0.400 0.006 
 Activities Given Up 0.02 (0.13) 0.28 (0.45)* < 0.001 0.138 0.13 (0.35) 0.16 (0.37) 0.662 0.002 
 Adverse Consequences 0.07 (0.25) 0.30 (0.46)* 0.001 0.090 0.15 (0.36) 0.21 (0.41) 0.452 0.005 
 Tolerance 0.03 (0.18) 0.28 (0.45)* < 0.001 0.111 0.17 (0.38) 0.15 (0.36) 0.685 0.001 
 Withdrawal 0.10 (0.30) 0.42 (0.50)* < 0.001 0.121 0.17 (0.38) 0.32 (0.47)* 0.042 0.035 
 Use Despite Problems 0.08 (0.28) 0.22 (0.41) 0.061 0.030 0.10 (0.30) 0.19 (0.40) 0.144 0.018 
 Failed Role Obligations 0.02 (0.13) 0.17 (0.38)* 0.006 0.063 0.10 (0.30) 0.09 (0.29) 0.880 0.000 
 Physically Hazardous Use 0.08 (0.28) 0.30 (0.46)* 0.002 0.079 0.21 (0.41) 0.18 (0.38) 0.621 0.002 
 Cravings 0.07 (0.25) 0.23 (0.43)* 0.012 0.053 0.12 (0.32) 0.18 (0.38) 0.348 0.008 
 Symptom Count 0.80 (3.35) 3.27 (3.45)* < 0.001 0.160 1.85 (2.89) 2.18 (3.12) 0.519 0.004 
Weight Gain in MDD 16 
Table 3:  
Endorsement rates for Yale Food Addiction Scale (YFAS) data, by Diagnosis and Sex (total 
N = 120; MDD and control participants). 
 
Note: MDD = Major Depressive Disorder; YFAS = Yale Food Addiction Scale. 
 
 
3.1.3 Leptin and Ghrelin 
 
Initial inspection of the distribution of the waist-circumference normalised leptin data 
across all participants indicated a positively skewed distribution (skewness = 6.448, SE = 
.231). The normalised leptin data were subsequently natural-log transformed (e.g. Milaneschi 
et al., 2012; Mills et al., 2018). Following log-transformation, three univariate outliers were 
detected, two of which were MDD participants with leptin levels below the limit of detection. 
Eleven participants (8 MDD, 3 control; 10 female) had reported insulin dysregulation issues 
(three had diabetes, two had insulin resistance and six had polycystic ovarian syndrome). In 
order to eliminate potential confounding effects, the univariate outliers and leptin data from 
all participants with insulin dysregulation disorders were excluded from subsequent leptin 
analyses (e.g. Mills et al., 2018). Means and standard deviations for the log-transformed 
  Sex Diagnosis 
  Male Female Control MDD 
  % % % % 
 Sample size (n) 52 68 60 60 
YFAS Increased Intake 26.92 20.59 13.33 33.33 
 Inability to Quit 15.38 29.41 10 36.67 
 Time Taken to Obtain 26.92 20.59 10 36.67 
 Activities Given Up 13.46 16.18 1.67 28.33 
 Adverse Consequences 15.38 20.59 6.67 30 
 Tolerance 17.30 14.71 3.33 28.33 
 Withdrawal 17.30 32.35 10 41.67 
 Use Despite Problems 9.61 19.12 8.33 21.67 
 Failed Role Obligations 9.61 8.82 1.67 16.67 
 Physically Hazardous Use 21.15 17.65 8.33 30 
 Cravings 11.54 17.65 6.67 23.33 
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leptin values are displayed in Table 4. Log-normalised leptin values did not differ between 
participants who elected to fast and those who did not (F(1, 102) = .103, p = .749). 
Accounting for age and BMI, log-normalised leptin values were not significantly 
different between MDD and control participants. Females had significantly higher log-
normalised leptin values than males (F(1, 100) = 110.391, p < .001). BMI was a significant 
covariate (F(1, 100) =77.460, p < .001), however Age as a covariate, and the interaction 
between Diagnosis and Sex, were non-significant. 
Means and standard deviations for the ghrelin data are also displayed in Table 4. 
Inspection of the ghrelin data indicated a normal distribution (skewness = .135, SE = .231), 
and no outliers in boxplot diagrams were detected. Participants reporting insulin 
dysregulation issues (n = 11) were also excluded from ghrelin analyses. Ghrelin values did 
not differ between fasting and non-fasting participants (F(1, 105) = .164, p = .686). 
Ghrelin values did not differ significantly between MDD and control participants, or 
by Sex, after accounting for age and BMI as potential covariates. BMI was identified as a 
significant covariate (F(1, 103) = 8.007, p = .006), however Age as a covariate and the 
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Table 4:  




Note: MDD = Major Depressive Disorder; BMI = Body Mass Index.  Leptin values normalised to waist circumference. Significance noted for 
log-transformed data.




D x S 
Interaction 




D x S 
Interaction 
  n M (SD) M (SD) p partial η2 p n M (SD) p partial η2 p 
Diagnosis Control 56 8.51 (13.44) 1.11 (1.58) 
0.173 0.018 
0.814 
57 2.77 (1.22) 
0.994 0.000 
0.668 
MDD 55 16.94 (38.80) 1.42 (1.90) 52 2.70 (1.25) 
Sex Male 48 3.10 (5.17) 0.13 (1.49) 
<0.001 0.525 
51 2.54 (1.10) 
0.150 0.020 Female 58 20.26 (36.66) 2.19 (1.32) 58 2.90 (1.31) 
Covariates Age  - - - 0.104 0.026 - - - 0.241 0.013 - 
BMI  - - - <0.001 0.436 - - - 0.006 0.072 - 
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3.2 Analysis by Appetite/Weight Change Sub-Groups in MDD 
 
All 60 MDD participants were categorised based on self-reported increases (n = 28), 
decreases (n = 25) or no changes (n = 7) to their appetite/weight from the clinical interview. 
Data from participants with increased appetite/weight were compared to those with decreased 
or unchanged appetite/weight (n = 32) combined. Further analyses were performed removing 
the seven participants with unchanged appetite/weight due to potential differences from 
participants experiencing appetite/weight dysregulation, however the results were equivalent 
in terms of significant effects and interactions. Hence, the results from the total sample are 
reported. There were 17 females and 11 males in the increased group, and 17 females and 15 
males in the decreased/unchanged group. The Appetite/Weight Categories did not differ in 
sex distributions (χ2 (1, N = 60) = .350, p = .554) or age. 
 Weight (F(1, 56) = 4.041, p = .049) and BMI (F(1, 56) = 7.480, p = .008) was 
significantly higher in participants reporting increased appetite/weight than those with 
decreased/unchanged appetite/weight. Participants with increased appetite/weight also scored 
significantly higher on the Emotional eating subscale of the DEBQ (F(1, 56) = 37.388, p < 
.001) and reported a greater number of YFAS food addiction symptoms (F(1, 56) = 13.650, p 
= .001) They also scored significantly higher on each of the YFAS subscales (data not 
shown). Sex differences for the biometric and psychometric data were as reported previously 
in sections 3.1.1 and 3.1.2.  
Following the exclusion of 10 MDD participants for insulin dysregulation issues as 
previously described (section 3.3), log-normalised leptin and ghrelin values did not differ 
between participants who elected to fast and those who did not, and they were not 
significantly different between those with increased or decreased/unchanged appetite/weight. 
BMI was a significant covariate in both analyses. Sex effects reflected those reported 
previously for the larger comparison (section 3.1.3). No further differences or interaction 
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effects based on Appetite/Weight Categories or Sex were identified. Means and standard 
deviations for the biometric, psychometric and endocrine data are displayed in Table 5.
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Table 5: 
Means and standard deviations for biometric, psychometric (N = 60), leptin (N = 50; ng/ml) and ghrelin (N = 52; ng/ml) by Appetite/Weight 
Categories (increased compared to decreased/unchanged) and Sex (MDD participants only). 
 
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours 
Questionnaire; YFAS = Yale Food Addiction Scale. # N = 50; normalised to waist circumference. 33 N = 52. * Indicates a significant difference 
compared to the other appetite/weight group or sex being compared. 
  Appetite/Weight Categories Sex 
Variables  Increased Decreased/Unchanged Effect Size Male Female Effect Size 
  M (SD) M (SD) p partial 
η2 
M (SD) M (SD) p partial 
η2 
 Sample Size (n) 28 32 - - 26 34 - - 
Biometrics Weight (kg) 78.37 (16.6) 71.4 (15.23) 0.49* 0.67 79.98 (16.48) 70.58 (14.82) 0.14* 0.104 
 BMI (kg/m2) 27.81 (4.99) 24.04 (5.20) 0.008* 0.118 25.21 (4.77) 26.25 (5.87) 0.580 0.006 
 Waist Circumference (m) 0.93 (0.14) 0.86 (0.14) 0.072 0.056 0.90 (0.13) 0.90 (0.15) 0.839 0.001 
BDI Total Score 31.96 (10.21)* 29.62 (9.02) 0.444 0.011 27.73 (9.44) 33.00 (9.18) 0.041* 0.072 
DEBQ Emotional Eating 3.49 (0.98)* 2.10 (0.75) <0.001* 0.400 2.41 (1.12) 3.01 (1.03) 0.024* 0.087 
 Restrained Eating 2.52 (0.97) 2.47 (1.17) 0.964 0.000 2.17 (1.01) 2.73 (1.07) 0.051 0.066 
 External Eating 3.35 (0.63) 3.08 (0.69) 0.087 0.051 3.10 (0.73) 3.30 (0.63) 0.447 0.010 
YFAS Symptom Count 4.96 (3.74) 1.78 (2.37) 0.001* 1.96 2.81 (3.31) 3.62 (3.57) 0.415 0.012 
Hormones Leptin (ng/ml)3 1.88 (2.00) 1.03 (1.74) 0.536 0.009 0.24 (1.66) 2.51 (1.40) <0.001* 0.506 
 Ghrelin (ng/ml)33 2.68 (1.39) 2.71 (1.14) 0.594 0.006 2.48 (1.16) 2.92 (1.31) 0.260 0.027 
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3.3 Correlation Analyses 
 
BMI correlated positively with Restrained (r(120) = .200, p = .028) and Emotional 
(r(120) = .274, p = .002) eating. Waist circumference also correlated positively with 
Emotional eating (r(120) = .248, p = .006). YFAS Symptom Count scores correlated 
positively with participant weight (r(120) = .217, p = .017), BMI (r(120) = .285, p = .002) 
and waist circumference (r(120) = .310, p = .001). Total BDI scores positively correlated 
with the Restrained (r(120) = .335, p < .001) and Emotional (r(120) = .462, p < .001) 
subscales of the DEBQ, and with the YFAS Symptom Count score (r(120) = .501, p < .001). 
YFAS Symptom Count scores further correlated with Restrained (r(120) = .216, p = .018), 
Emotional (r(120) = .548, p < .001) and External (r(120) = .211, p = .020) eating. 
Log-normalised leptin values correlated positively with weight (r(106) = .203, p = 
.037), BMI (r(106) = .490, p < .001) and waist circumference (r(106) = .378, p = < .001). 
Log-normalised leptin values correlated positively with Emotional (r(106) = .334, p < .001) 
and Restrained (r(106) = .366, p = < .001) eating, and the Failure to Quit (r(106) = .289, p = 
.003), Adverse Consequences (r(106) = .198, p = .042) and Continued Use Despite Problems 
(r(106) = .218, p = .025) subscales of the YFAS. Ghrelin values correlated negatively with 
weight (r(109) = -.239, p = .012), BMI (r(109) = -.247, p = .010) and waist circumference 




The current study examined relationships between disordered eating, the 
hunger/satiety hormones ghrelin and leptin and symptomatic weight changes in MDD. It was 
found that disordered eating was higher in MDD than controls, in females than males, and in 
a subset of depressed individuals with appetite/weight gain compared to 
decreased/unchanged appetite/weight. Leptin levels correlated positively, and ghrelin 
negatively, with disordered eating. 
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Emotional and restrained eating behaviours were higher in MDD than controls. Food 
addiction symptoms were also higher in MDD, with 28% of MDD participants compared to 
3% of control participants meeting the Yale criteria for food addiction; double that reported 
in general community samples (Meule & Gearhardt, 2014) and replicating our earlier 
findings (Mills et al., 2018). These findings align with previous studies indicating that MDD 
is associated with increased emotional (e.g. van Strien et al., 2016; Paans et al., 2018), 
restrained (e.g. Sevincer et al., 2017) and food addiction eating behaviours (e.g. Eichen et al., 
2013; Gearhardt et al., 2012). Consistent with our previous study, emotional eating and food 
addiction were also higher in females compared to males (e.g. Mills et al., 2018). In addition, 
they were higher in participants in the MDD subgroup who had increased compared to 
reduced or unchanged appetite/weight, consistent with previous research identifying a higher 
prevalence of these behaviours in overweight and obese populations compared to normal 
weight controls (e.g. Bailly et al., 2012). These findings provide evidence in support of 
dysregulated appetite and food intake patterns in MDD, particularly in females. Increased 
intake of highly palatable foods and related behaviours may be used to minimise 
psychological distress or dampen physiological stress responses produced by the HPA axis 
(e.g. Dallman et al., 2003; Leow et al., 2018), therefore acting as a potential coping 
mechanism for stress or low mood. This is supported by the positive associations between 
MDD symptom severity, emotional eating and food addiction. Given that increased food 
intake and emotional eating have been linked to weight fluctuations (e.g. Keller & Siegrist, 
2015), these findings provide support for such behaviours acting as potential risk factors for 
weight gain in those with increased appetite/weight in MDD, particularly females.  
Leptin levels were positively correlated with emotional and restrained eating, and 
food addiction symptoms including loss of control in food consumption and continuing to eat 
despite negative consequences. Leptin was also positively associated with BMI and weight. 
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The associations between problematic eating behaviours and leptin are consistent with our 
previous study (Mills et al., 2018), which identified that disordered eating was correlated 
with leptin levels. Higher leptin levels correlating positively with measures of emotional 
eating and food addiction relating to increased food intake lead to the suggestion of possible 
leptin resistance, because higher leptin levels would normally be expected to be associated 
with satiety rather than behaviours related to increased food intake. In the current study we 
provide new information about the relationships between ghrelin and some eating behaviours, 
with ghrelin levels negatively correlating with restrained eating. This suggests that 
individuals with higher ghrelin levels may be more likely to experience hunger and increased 
food intake, with a lower degree of control over these behaviours. Comfort eating in MDD is 
often viewed as having psychological underpinnings (e.g. Leow et al., 2018), however the 
associations between leptin, ghrelin and disordered eating in MDD suggest that excessive 
eating behaviours are also related to physiological pathways, which is relevant to intervention 
approaches. Further research is required to assess the temporal nature and causal relationships 
between these variables. 
Leptin and ghrelin levels did not differ significantly by diagnosis, consistent with 
some previous studies investigating leptin (e.g. Carvalho et al., 2014; Mills et al., 2018) and 
ghrelin (e.g. Kluge et al., 2009; Matsuo et al., 2012) levels in MDD, but are in contrast to 
other studies reporting either elevated or lowered levels (e.g. Antonijevic et al., 1998; Ozsoy 
et al., 2014). The inconsistencies in findings may be due to the heterogeneous nature of 
symptom profiles in MDD, which has not been a notable factor in previous research. 
However, in the current study, neither leptin or ghrelin levels differed significantly by 
appetite/weight symptom profile. These findings, in combination with the aforementioned 
correlations, suggest that leptin and ghrelin may be specifically linked to disordered eating 
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behaviours in MDD as opposed to the disorder more generally, and differences may not be 
clearly discernable in between-groups analyses. 
Clear sex differences were observed in relation to leptin levels, with females having 
higher waist-normalised leptin levels than males. These results are consistent with previous 
findings (e.g. Antonijevic et al., 1998; Mills et al., 2018). Because females store more body 
fat for reproductive purposes (Blaak, 2001), and leptin secretion is proportional to adipose 
tissue mass (Maffei et al., 1995), females may have naturally higher leptin levels. No sex 
difference was observed in ghrelin levels, consistent with some previous studies (e.g. Tschop 
et al., 2001) but in contrast to others (e.g. Soriano-Guillen et al., 2016), indicating that further 
research is required to examine ghrelin levels in relation to depressogenic weight gain in 
females also. 
These findings help to better understand potential biological, psychological and 
behavioural pathways associated with depressogenic weight gain, which have previously not 
been studied in unison. While we did not find an influence of MDD or depression subtypes in 
leptin levels, their significant correlation with problematic eating behaviours warrants further 
investigation. Collectively, the identified variables represent promising targets for research 
into potentially modifiable risk factors for disordered eating behaviours, which may act as 
risk factors for weight gain in MDD. If increased leptin occurs in the absence of satiety 
behaviours, but rather in association with depressogenic increased eating corresponding to 
leptin resistance, this may be a potential therapeutic target to address problematic eating and 
weight gain risk in a large subset of individuals with MDD, particularly females. The 
potential of leptin as a therapeutic target for other symptoms in MDD is currently being 
considered (Ge et al., 2018), however its potential role in weight gain associated with MDD 
has received little consideration to date. 
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 There are some limitations of the study which need to be considered. Participants 
were not required to fast prior to blood sampling; previous leptin and ghrelin studies have 
used both fasting and non-fasting protocols (e.g. Milaneschi et al., 2017; Mills et al., 2018). 
Previous research has found that non-fasting leptin levels are not significantly different from 
fasting leptin levels (e.g. Hancox & Landhuis, 2011). Additionally, ghrelin levels maintain 
characteristic meal-related changes at meal times even when fasting (e.g. Natalucci et al., 
2005). We did compare subgroups of participants who had not consumed food or drink for 
12h with those who had and did not find significant hormonal differences, however use of 
differing protocols should be considered when interpreting hormone results. Potential 
confounding variables, such as participants’ dietary nutrient intake, physical activity levels 
and menstrual phase in female participants were also not controlled for. Much previous leptin 
research does not include information on physical activity or menstrual phase (e.g. Ozsoy et 
al., 2014; Milaneschi et al., 2017), however these factors should be considered in future 
studies. This study is also limited by its cross-sectional design. Longitudinal research is 
necessary to examine temporal relationships, if any, between disordered eating, appetite 
hormones and weight gain in MDD. 
In conclusion, the current study provides new information regarding problematic 
eating behaviours in MDD and their relationships to hormones and other symptoms. While 
comfort eating in MDD is often viewed as an emotional issue, the results suggest that self-
reported excessive eating in MDD correlates with appetite hormones, implying that these 
behaviours may have a greater physiological basis than previously understood, related to 
appetite and core depressive symptoms. The results also suggest that leptin dysregulation 
may be important to depressogenic excessive eating and weight gain, representing a potential 
treatment target for weight gain and associated chronic disease in individuals affected by 
MDD, particularly females. Future longitudinal research is warranted into these factors.   
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